Reference Curves for Bone Mineral Density and Body Composition in Women Aged 20-89
NCT ID: NCT06983587
Last Updated: 2025-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
425 participants
INTERVENTIONAL
2025-06-01
2029-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Some 425 healthy female volunteers aged 20 to 89 will be recruited from three centers (Nîmes, Montpellier and Lyon). A bone density scan at various bone sites (femur, rachis, radius and whole body) will provide up-to-date normalcy curves for bone mineral density as well as body composition (fat and lean mass). These measurements should help to better understand bone physiology and the links that may exist between bone tissue and muscle and adipose tissue.
This is a prospective multicenter cross-sectional descriptive study of healthy female volunteers. The study population is made up of healthy female volunteers from Europe, the Middle East and North Africa aged between 20 and 89, stratified into 7 age groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Body Composition Via Dual-energy X-ray Absorptiometry Bone Densitometry
NCT02609191
Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98
NCT00369850
Evaluation of Agreement Between CT Scan and 3D-DXA Measurements on the Lombar Spine
NCT03638674
Smallest Significant Value in Osteodensitomery in an Obese Population
NCT04301427
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
NCT00587925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
So far, only one reference curve has been obtained in France, from the OFELY study in 1993.
Given the age of this cohort and the possibility of changes in BMI over time in the population of European, Middle Eastern and North African origin, but even more so, the impossibility of transposing this curve onto new DXAs of different brands, new reference curves need to be developed. DMS IMAGING is therefore financing the MONIKA study, with Nîmes University Hospital as sponsor.
As part of this study, some 425 healthy female volunteers aged between 20 and 89 will be recruited from three centers (Nîmes, Montpellier, Lyon). A DXA examination at various bone sites (femur, rachis, radius and whole body) will provide up-to-date normalcy curves for BMD, but also for body composition (fat and lean mass), which are currently lacking. Access to this population could also enable us to better understand bone physiology and the links that may exist between bone tissue and muscle and adipose tissue.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women aged 20-29
This group will be used to construct the T-score equation, and thus define the thresholds for osteopenia and osteoporosis. To ensure adequate precision for this T-score, 175 subjects will be included in this age group. With this number of subjects, the following accuracies for two of the sites of interest (hip and L1-L4) are expected:
For the hip, the expected bone mineral density value is 0.95 (SD=0.11) according to local data consistent with Arlot et al. Inclusion of 175 subjects would give a ½ width 95% confidence interval (IC95%) of the mean would be around 0.016, and the half width standard deviation of 0.012 For L1-L4, the expected bone mineral density value is 0.99 (SD=0.11) according to local data consistent with Arlot et al. The ½ width of the 95% confidence interval (IC95%) of the mean would be around 0.016, and the half-width standard deviation of 0.012.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 30-39
For the 30-39 age group, only 25 subjects will be included, given the constancy of bone mineral density in this age group compared with the 20-29 age group. In addition, the results of the analyses will take the form of a Z-score equation, estimated using a regression method (i.e. overall and not a z-score per age group). As there will be many subjects under 30 and over 40, this will ensure (by interpolation) an equivalent precision in these age brackets to that of the adjacent age categories.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 40-49
Group including 50 subjects.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 50-59
Group including 50 subjects.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 60-69
Group including 50 subjects.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 70-79
Group including 50 subjects.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Women aged 80-89
Only 25 subjects will be included in this age group for reasons of feasibility.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bone densitometry scan
Each study participant will undergo a bone density measurement scan. The equipment used in this study will be the STRATOS DR X-ray bone densitometer (APELEM, 9 Avenue du Canal Philippe Lamour, 30660 Gallargues-le-Montueux, France). This device is indicated for diagnosing osteoporosis, assessing the risk of fracture in weakened bone areas, monitoring bone density, monitoring body composition and diagnosing vertebral anomalies (vertebral compression, fractures).
In general, the time for a scan is less than 1 min for the spine, less than than 1 min for the femur, less than 1 min for the forearm and around 4 min for the whole body.
The total duration of the patient's participation in this research will be approximately 2 hours.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person affiliated to or benefiting from a social security scheme
* Free, informed consent signed by the participant and the investigator (on the day of inclusion and before any examination required by the research).
Exclusion Criteria
* Fragility fracture defined as a spontaneous or low-kinetic fracture (≤ one fall from height)
* Hip fracture in a first-degree relative
* Early menopause (\< age 40), Hysterectomy (complete \< age 40), Primary amenorrhea (absence of menstruation before age 15), Current amenorrhea of more than 3 months without contraceptive if patient is under age 40
* Treatments : Prolonged corticosteroid therapy \> 3 months or \> 1 g (cumulative dose)
* Immobilization of more than 3 months, less than 12 months old
* Patients presenting one of the following pathologies affecting bone, muscle or adipose tissue:
* Chronic inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis) and untreated celiac disease
* Renal insufficiency on dialysis or patients with nephrology follow-up
* Known hypercalciuria
* Osteomalacia, rickets, osteogenesis imperfecta
* Osteopathy (Paget's disease, osteopetrosis, etc.)
* Chronic inflammatory rheumatism
* Haemopathy, neoplasia
* Hepatic insufficiency or chronic hepatitis
* Endocrinopathy: dysthyroidism, hypogonadism, hypercorticism, untreated acromegaly.
* Anorexia nervosa
* Hyperparathyroidism (even if controlled)
* History of digestive surgery (bariatric, gastrectomy, digestive resection other than appendectomy, etc.)
* History of organ transplant
* Chronic infectious disease (HIV, etc.)
* Weight loss of more than 10 kg in the last 6 months
* Paresis, marked lameness or unloading of a limb or prolonged immobilisation of more than one month in the last 12 months
All patients on any treatment that may affect bone mass or body composition:
* Biphosphonates (Alendronate (Fosamax® and generics), Risedronate (Actonel® and generics), Zoledronate (Aclasta® and generics)
* Teriparatide (Forsteo®)
* Denosumab (Prolia®)
* Selective oestrogen receptor modulator (Clomifen, Tamoxifen, Toremifen, Raloxifen)
* Anabolic steroids.
* Strontium ranelate
* Carbamazepine
* Phenobarbital
* Immunosuppressants
* Antiepileptics
All patients with one of the following anomalies in the measurement area:
* Major deformities of the wrist, hip or vertebrae
* Compression of the vertebral bodies, cementoplasty
* Prosthesis, implant (breast, buttock, etc.), foreign body
* Hip paraosteoarthropathy
* Injection of radiological contrast product, barium enema, nuclear medicine examination within 10 days
Miscellaneous :
* Intensive sport (more than 10 h/week).
* Extreme BMI (BMI \< 18, BMI \> 35 kg/m²).
* Loss of autonomy
* Pregnant, parturient or breast-feeding woman
* Participation in an interventional study involving a drug or medical device or a category 1 RIPH in the 3 months prior to inclusion.
20 Years
89 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Hôpital Edouard Herriot
OTHER
Centre Hospitalier Universitaire de Nīmes
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Montpellier, Hérault, France
Hôpital E Herriot UMR_S 1033
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDIL/2023/VB-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.